Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Total Assets
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) holds total assets worth CN¥8.59 Billion CNY (≈ $1.26 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Shanghai Allist Pharmaceuticals Co. Ltd. (688578) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Total Assets Trend (2017–2025)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Shanghai Allist Pharmaceuticals Co. Ltd. to evaluate the quality of earnings relative to operating cash generation.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Allist Pharmaceuticals Co. Ltd. A's total assets of CN¥8.59 Billion consist of 52.8% current assets and 47.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥375.60 Million | 4.8% |
| Inventory | CN¥71.66 Million | 0.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥349.63 Million | 4.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Allist Pharmaceuticals Co. Ltd. (688578) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Allist Pharmaceuticals Co. Ltd. A's current assets represent 52.8% of total assets in 2025, a decrease from 79.6% in 2017.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, down from 11.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 4.8% of total assets.
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Shanghai Allist Pharmaceuticals Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.25 | 7.80 | 24.23 |
| Quick Ratio | 5.17 | 7.75 | 24.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.51 Billion | CN¥3.91 Billion | CN¥2.45 Billion |
Shanghai Allist Pharmaceuticals Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai Allist Pharmaceuticals Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.84 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | 33.6% |
| Total Assets | CN¥7.90 Billion |
| Market Capitalization | $5.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Allist Pharmaceuticals Co. Ltd. A's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shanghai Allist Pharmaceuticals Co. Ltd. A's assets grew by 33.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2025)
The table below shows the annual total assets of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.90 Billion ≈ $1.16 Billion |
+33.61% |
| 2024-12-31 | CN¥5.92 Billion ≈ $865.72 Million |
+35.18% |
| 2023-12-31 | CN¥4.38 Billion ≈ $640.42 Million |
+27.14% |
| 2022-12-31 | CN¥3.44 Billion ≈ $503.70 Million |
+9.96% |
| 2021-12-31 | CN¥3.13 Billion ≈ $458.06 Million |
+4.79% |
| 2020-12-31 | CN¥2.99 Billion ≈ $437.10 Million |
+124.86% |
| 2019-12-31 | CN¥1.33 Billion ≈ $194.39 Million |
+254.25% |
| 2018-12-31 | CN¥375.00 Million ≈ $54.87 Million |
-26.27% |
| 2017-12-31 | CN¥508.63 Million ≈ $74.43 Million |
-- |
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more